Lineage Cell Therapeutics, Inc. Share Price

Lineage Cell Therapeutics, Inc. Share Price

AMEX: LCTX | Micro Cap
$1.05
+$0.02 (2.43%) Last updated on 29 Oct, 2026 | 19:53 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Lineage Cell Therapeutics, Inc. Stock Performance

Open
$1.04
Prev. Close
$1.03
Circuit Range
N/A
Day Range
$1.04 - $1.05
Year Range
$0.88 - $2.08
Volume
2,151
Average Traded
$1.05

Lineage Cell Therapeutics, Inc. Share Price Today

As of 29 October 2026, Lineage Cell Therapeutics, Inc.'s share price is $1.05. The stock opened at $1.04, compared to its previous close of $1.03. During today's trading session, Lineage Cell Therapeutics, Inc.'s share price traded between $1.04 and $1.05, with an average price of $1.05. Over the past 52 weeks, the stock has recorded a high of $2.08 and a low of $0.88. In terms of performance, Lineage Cell Therapeutics, Inc.'s share price has declined by 30.59% over the last six months and is down 45.19% on a year-on-year basis.

Lineage Cell Therapeutics, Inc. Share Price Chart

Line chart of the Lineage Cell Therapeutics, Inc. price trend over the selected period. The price rose overall, ranging from 1.04 to 1.05, ending at 1.05.
$1.04$1.05
L
Show Current Price
H

Lineage Cell Therapeutics, Inc. Stock Fundamentals & Key Indicators

Market Cap
$242.77M
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.13
Revenue (TTM)
$14.56B
Return On Equity (TTM)
-52.96%
Profit Margin
-436.33%
Debt to Equity
0.00
Quarterly Earnings Growth YoY
84.21%

Lineage Cell Therapeutics, Inc. Quarterly Profit & Loss

All figures in USD

ParticularsJun 2025Sep 2025Dec 2025Mar 2026
Revenue$2.77$3.68$6.61$1.73
Net Profit-$30.46-$29.78$0.85-$4.81
Net Profit Margin-1099.64%-809.24%12.86%-278.03%
Income ChangeN/A2.23%102.85%-665.88%

Lineage Cell Therapeutics, Inc. Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$14.70$8.95$9.50$14.56
Net Profit-$26.27-$21.49-$18.61-$63.53
Net Profit Margin-178.71%-240.11%-195.89%-436.33%
Income ChangeN/A18.20%13.40%-241.38%

About Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Lineage Cell Therapeutics, Inc. Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$0.95
$1.05
+11.40%
Sep 2026
$1.11
$0.95
-19.06%
Aug 2026
$1.09
$1.17
+7.83%
Jul 2026
$1.32
$1.08
-17.49%
Jun 2026
$1.34
$1.31
-0.38%
May 2026
$1.50
$1.32
-13.16%
Apr 2026
$1.58
$1.52
-3.18%
Mar 2026
$1.88
$1.57
-18.02%
Feb 2026
$1.48
$1.92
+31.16%
Jan 2026
$1.66
$1.46
-12.31%
Dec 2025
$1.72
$1.67
-4.86%
Nov 2025
$1.97
$1.75
-9.09%

LCTX Share Price FAQs